Merck KGaA has announced that it has agreed to buy Sigma-Aldrich for $140 per share in cash, or a total of $17 billion.
Merck KGaA has announced that it has agreed to buy Sigma-Aldrich for $140 per share in cash, or a total of $17 billion. The purchase will expand the reach of Merck’s EMD Millipore chemical and equipment division, “increasing the company’s presence in North America and adding exposure to fast-growing Asian markets,” according to a press release from EMD. Sigma-Aldrich is a life-sciences company that specializes in products used in scientific R&D in fields such as biotechnology, genomics, and pharmaceuticals.
Merck said the transaction will be immediately accretive to Merck KGaA, and Sigma-Aldrich will become part of Millipore. The acquisition is touted to be the largest in Merck’s history.
Merck Chairman of the Executive Board Karl-Ludwig Kley said in an interview that with this acquisition, Merck is doubling its business earnings for the academia and lab markets. “Currently we are under-represented in the US and with the strong presence of Sigma-Aldrich in the US market, we’ll have a size which really allows us to take products and service to the customer throughout this great country.”
The transaction is expected to close by mid-2015. Merck expects annual synergies of about €260 million (approximately $333 million), which should be fully achieved within three years after closing, pending regulatory approval.
FDA Approves Samsung Bioepis Biosimilars Ospomyv and Xbryk
February 18th 2025Ospomyv, a biosimilar to Prolia, is indicated for postmenopausal women and men at high risk of fracture, while Xbryk, a biosimilar to Xgeva, is indicated for preventing skeletal-related events in multiple myeloma and solid tumor bone metastases.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.